CERo Therapeutics Holdings, Inc.
CERO
$0.8899
-$0.0579-6.11%
NASDAQ
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 6.00% | -7.67% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -52.40% | -14.49% | |||
| Operating Income | 52.40% | 14.49% | |||
| Income Before Tax | 115.89% | -72.66% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 115.89% | -72.66% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 115.89% | -72.66% | |||
| EBIT | 52.40% | 14.49% | |||
| EBITDA | 53.38% | 14.81% | |||
| EPS Basic | 80.02% | 43.70% | |||
| Normalized Basic EPS | 74.78% | 52.39% | |||
| EPS Diluted | 80.02% | 43.70% | |||
| Normalized Diluted EPS | 74.78% | 52.39% | |||
| Average Basic Shares Outstanding | 150.14% | 206.67% | |||
| Average Diluted Shares Outstanding | 150.14% | 206.67% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||